Article

Statin use may cause certain eye disorders, according to study

Eye disorders related to statin use were reported in the Jupiter Study led by F.W. Fraunfelder, MD, Casey Eye Institute, Oregon Health & Sciences University.

Portland, OR-Eye disorders related to statin use were reported in the Jupiter Study led by F.W. Fraunfelder, MD, Casey Eye Institute, Oregon Health & Sciences University. The medication used to lower patients’ cholesterol levels, thus helping prevent coronary heart disease, stroke, and other deaths related to high cholesterol levels, is related to certain eye disorders in about 0.1% of patients.

Statin-associated reports of diplopia, ptosis, and ophthalmoplegia in the databases of the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the FDA were analyzed. Average patient age was 64.5 years; case reports include 143 males, 91 females, and 22 persons with gender unspecified.

The average statin doses of patients with one or more eye disorders was within ranges recommended by drug manufacturers. The average time from beginning of therapy to developing an adverse drug reaction was 8.3 months.

Twenty-three cases of loss of eye range of motion, eight cases of ptosis, and 18 cases of ptosis in conjunction with double vision occurred. Disorders in all patients apparently resolved completely when statins were discontinued, but researchers could not determine which eye muscles were involved or time needed to fully recover after statin discontinuation, for individual cases.

"We advise physicians prescribing statins to be aware that these eye disorders may result and that medications should be discontinued if so. When a patient has one of these eye disorders, he should be rigorously evaluated to determine the cause, and statin use should be taken into account," Dr. Fraunfelder concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.